天美传媒

Practicing internal medicine physician who has served as chairman and CEO of the Virginia Mason Health System in Seattle since 2000. He is also chair of the National Patient Safety Foundation Lucian Leape Institute and immediate past chair of the Institute for Healthcare Improvement Board of Directors. During his tenure as chief executive, Virginia Mason has become a national leader in quality, safety and innovation resulting from its Toyota Production System-inspired lean management methodology, the Virginia Mason Production System. To schedule an interview with Dr. Kaplan, contact Virginia Mason Media Relations.

Deborah A. Pasko, Pharm.D., M.H.A., is the Sr. Director of Medication Safety and Quality at ASHP (American Society of Health-System Pharmacists). With more than 22 years of pharmacy practice experience, Dr. Pasko leads ASHP鈥檚 efforts to improve medication safety and reduce opioid misuse. 

Dr. Pasko鈥檚 role at ASHP includes working with the Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Department of Health and Human Services (HHS), and the White House on national medication safety initiatives. She also serves as an advisor to the Institute for Safe Medication Practices (ISMP), the Joint Commission (TJC), the United States Pharmacopeia (USP) National Coordinating Council for Medication Error Reporting and Prevention (NCC-MERP) safety committee, and the National Quality Forum (NQF). 

Dr. Pasko earned her Bachelor of Pharmacy degree from the Ohio Northern University College of Pharmacy and her Doctor of Pharmacy degree from Idaho State University College of Pharmacy. She has a Masters of Health Administration from the Walden University School of Health Sciences and completed a fellowship in Nephrology and Critical Care at the University of Michigan College of Pharmacy. Dr. Pasko has received numerous awards including the Cheers Award for Medication Safety. 

, is the director of Moores Cancer Center at UC San Diego Health. She provides the overall strategic and intellectual direction for the center’s research programs, administrative structure, and multidisciplinary cancer clinical care. She serves as the principal investigator for the Cancer Center’s support grant sponsored by the National Cancer Institute (NCI).
Simeone, a , partners with academic and clinical leaders to guide cancer research and care and provides counsel to campus and university-level committees. She manages day-to-day operations, including scientific, education, and clinical programs.
Prior to her current role, Simeone served as the director of the Pancreatic Cancer Center and was the associate director of translational research at Perlmutter Cancer Center at New York University Langone Health. She is an internationally renowned pancreatic surgeon and researcher with a long-standing career focused on treating pancreatic cancer and pancreatic cystic tumors. Throughout her career, she has driven innovation in cancer care by building a continuum between scientific discovery and new approaches for cancer detection and treatment. She has published more than 230 studies in leading peer-reviewed journals.
Simeone served as the chair of the scientific and medical advisory board of the Pancreatic Cancer Action Network and is a past president of the American Pancreatic Association and Society of University Surgeons. She is an elected member of the National Academy of Medicine and is a member of the National Cancer Institute (NCI) Pancreatic Cancer Task force and the NCI Cancer Centers Study Section. She also serves on the Board of Directors for the National Comprehensive Cancer Network.
She is the principal investigator and lead of Precision Promise, a national clinical trials consortium focused on next-generation clinical trials for people with pancreatic cancer. She is also the founder of the Pancreatic Cancer Early Detection (PRECEDE) Consortium, an international consortium established to drive the early detection of pancreatic cancer.